Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
:PTX
Holding AU:PTX?
Track your performance easily
PTX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.07
Previous CloseN/A
Volume766.17K
Average Volume (3M)879.49K
Market Cap
AU$35.43M
Enterprise ValueAU$16.42M
Total Cash (Recent Filing)$7.67M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Feb 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding805,319,760
10 Day Avg. Volume503,387
30 Day Avg. Volume879,490
Standard Deviation0.27
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)120.05
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Prescient Therapeutics Limited News
PremiumCompany Announcements
Prescient Therapeutics Reports Expiry of 1 Million Options
PremiumCompany Announcements
Prescient Therapeutics Gains FDA Approval for PTX-100 Trial
PremiumCompany Announcements
Prescient Therapeutics Appoints New CEO for Growth
PremiumCompany Announcements
Prescient Therapeutics Director Increases Stake in Future Growth
PremiumCompany Announcements
Prescient Therapeutics Expands Cancer Treatment Innovations
PremiumCompany Announcements
Prescient Therapeutics Announces Key AGM Outcomes
PremiumCompany Announcements
Prescient Therapeutics Warns of Investment Risks
PremiumCompany Announcements
Prescient Therapeutics Advances PTX-100 in Cancer TrialsOptions Prices
Currently, No data available
---
Ownership Overview
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.07 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$35.43M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Feb 21, 2025 which is in 33 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Aug 25, 2024. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 805,319,760 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
---
Prescient Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.96%
12-Months-Change
Fundamentals
Return on Equity
-37.32%
Trailing 12-Months
Asset Growth
-27.45%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia.
---
Technical Analysis
Althea Group Holdings Ltd.
―
Advaxis
―
Verastem
―
Akari Therapeutics
―
Agenus
―
Immutep
―
---